Linda Claudette Stork MD

Pediatric Hematology & Oncology•Portland, OR

Associate Professor of Pediatrics, Oregon Health & Sci University

Join to View Full Profile

3181 Sw Sam Jackson Park RdPortland, OR 97239
Phone+1 503-494-0829

Education & Training

University of ColoradoFellowship, Pediatric Hematology/Oncology, 1982 - 1986
University of ColoradoResidency, Pediatrics, 1981 - 1982
New York Presbyterian Hospital (Columbia Campus)Residency, Pediatrics, 1979 - 1981
Columbia University Vagelos College of Physicians and SurgeonsClass of 1979

Certifications & Licensure

WA State Medical License 2023 - 2026
OR State Medical License 2002 - 2025
CO State Medical License 1982 - 2003
American Board of Pediatrics Pediatrics
American Board of Pediatrics Pediatric Hematology-Oncology

Awards, Honors, & Recognition

Portland Monthly Magazine Castle Connolly, 2011

Clinical Trials

Combination Chemotherapy in Treating Children With Newly Diagnosed Acute Lymphoblastic Leukemia Start of enrollment: 1996 May 01
Completed
Phase 3
Pemetrexed Disodium in Treating Young Patients With Recurrent Solid Tumors Start of enrollment: 2003 Oct 01
Completed
Phase 1
Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia Start of enrollment: 2005 Apr 11
Completed
Phase 3
Collecting and Storing Malignant, Borderline Malignant Neoplasms, and Related Samples From Young Patients With Cancer Start of enrollment: 2003 Oct 13
Completed
Biomarkers in Tumor Tissue Samples From Patients With Newly Diagnosed Neuroblastoma or Ganglioneuroblastoma Start of enrollment: 2000 Nov 06
Recruiting
Risk-Based Therapy in Treating Younger Patients With Newly Diagnosed Liver Cancer Start of enrollment: 2009 Sep 14
ACTIVE_NOT_RECRUITING
PHASE3
Risk-Based Classification System of Patients With Newly Diagnosed Acute Lymphoblastic Leukemia Start of enrollment: 2010 Aug 09
Completed
Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia Start of enrollment: 2011 Jun 20
ACTIVE_NOT_RECRUITING
PHASE3
Intergroup Trial for Children or Adolescents With B-Cell NHL or B-AL: Evaluation of Rituximab Efficacy and Safety in High Risk Patients Start of enrollment: 2012 Jun 01
Brentuximab Vedotin or Crizotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II-IV Anaplastic Large Cell Lymphoma Start of enrollment: 2013 Nov 13
Completed
Phase 2
Adavosertib and Irinotecan Hydrochloride in Treating Younger Patients With Relapsed or Refractory Solid Tumors Start of enrollment: 2014 Mar 28
Completed
Phase 1, Phase 2
Talazoparib and Temozolomide in Treating Younger Patients With Refractory or Recurrent Malignancies Start of enrollment: 2014 May 16
Completed
Phase 1, Phase 2
Immunotherapy Before and After Surgery for Treatment of Recurrent or Progressive High Grade Glioma in Children and Young Adults Start of enrollment: 2020 Oct 02
RECRUITING
PHASE1
Roles: Contact
Fimepinostat in Treating Brain Tumors in Children and Young Adults Start of enrollment: 2019 Aug 07
ACTIVE_NOT_RECRUITING
EARLY_PHASE1
Roles: Contact
BGB-290 and Temozolomide in Treating Isocitrate Dehydrogenase (IDH)1/2-Mutant Grade I-IV Gliomas Start of enrollment: 2019 Apr 03
RECRUITING
PHASE1
Roles: Principal Investigator, Contact
Join now to see all

Publications & Presentations

PubMed

8 citations
Functional impact and targetability of,, andmutations in a spindle cell rhabdomyosarcoma with MYOD1 L122R mutation.
Florence Choo, Igor Odintsov, Kevin Nusser, Katelyn S Nicholson, Lara Davis
Cold Spring Harbor Molecular Case Studies. 2022-01-01
24 citations
Favorable Trisomies and ETV6-RUNX1 Predict Cure in Low-Risk B-Cell Acute Lymphoblastic Leukemia: Results From Children's Oncology Group Trial AALL0331
Leonard A. Mattano, Meenakshi Devidas, Kelly W. Maloney, Cindy Wang, Alison M. Friedmann
Journal of Clinical Oncology. 2021-03-19
7 citations
Parental decision making regarding consent to randomization on Children's Oncology Group AALL0932.
Kellee Parker, Erika Cottrell, Linda C. Stork, Susan Lindemulder
Pediatric Blood & Cancer. 2021-01-26

Grant Support

CCG 2961: Children W/ Untreated AML Immune Modulation Phase W/ IL 2National Center For Research Resources1999–2000
Pilot Trial With 6 ThioguanineNational Center For Research Resources1996–1997

Linda Claudette Stork MD

Dr. Stork is on Doximity

Education & Training

Certifications & Licensure

Awards, Honors, & Recognition

Clinical Trials

Publications & Presentations

Grant Support

Viewing the full profile is available to verified healthcare professionals only.